UP-22 Characteristics and outcomes of real-world patients with metastatic castrate-resistant prostate cancer (mCRPC) in Alberta, Canada.
Thursday June 27, 2019 from
TBD
Award Winner
Lawrence Mbuagbaw, Canada has been granted the
Presenter

Lawrence Mbuagbaw, Canada

Associate Professor

McMaster University

Abstract

Characteristics and outcomes of real-world patients with metastatic castrate-resistant prostate cancer (mCRPC) in Alberta, Canada

Lawrence Mbuagbaw2, Winson Cheung1,4, Shiying Kong4, Jennifer Lowther3, Richard Lee-Ying1,4.

1Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada; 2Biostatistics, McMaster University, Hamilton, ON, Canada; 3Bayer Inc, Mississauga, ON, Canada; 4University of Calgary, Calgary, AB, Canada

REACTIVATE; NCT04281147.

Introduction: The purpose of this real-world study is to describe the clinical characteristics and outcomes for mCRPC patients who received at least 2 lines of life-prolonging therapy (LPT) for mCRPC in the province of Alberta.

Methods: We used administrative databases in Alberta (2012-2017) to collect and describe patient characteristics (age, use of opioids, Charlson Comorbidity Index [CCI], lines of therapy, and use of bone health agents) and clinical outcomes (overall survival [OS] from start of 2nd line LPT, event free survival [EFS1: time from 2nd line LPT to 3rd line LPT or death; EFS2: time from 2nd line LPT to 4th line LPT or death]; and time to External Beam Radiation Therapy [EBRT]). Cox regression models were used to analyze time to event outcomes.

Results: Data from 724 men with a mean age of 65.4 years (standard deviation [SD] 8.8) in Alberta were included. Patients received a mean of 2.7 (SD 0.8) lines of therapy and were mostly treated at an urban center (71.7%).  Additional patient characteristics are described in Table 1. Use of opioids had an association with an improvement on all clinical endpoints, age with OS alone and the use of bone health agents with EFS1 alone. In the cohort, 69.1% have died and of the patients who died, 427 (59%) died of their cancer. The median OS was 347.5 days (interquartile range [IQR] 186-575.5). The median EFS1 (n=617/85.2%) was 205.5 days (IQR 107-357.5) while median EFS2 (n=539/74.4%) was 319 days (IQR 178.5-511.5). In the cohort, 353 (48.8%) required EBRT and the median time to first EBRT was 222 days (IQR 109-420).

Conclusions: These findings describe mCRPC patients receiving at least 2 lines of LPT and their outcomes in a real-world setting. These data can be used to inform the design of future pragmatic trials that better represent real-world patients. These data will also be used in future research combining population-based data from three additional Canadian provinces (REACTIVATE NCT04281147).


© 2022 CUA 74th Annual Meeting